Clinical Trial Update: Retifanlimab and Ruxolitinib In Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of retifanlimab and ruxolitinib in solid malignancies is currently recruiting, including non-small cell lung cancer and renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Retifanlimab (retifanlimab)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of California, San Diego | Conditions: Non Small Cell Lung Carcinoma, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING